Ann: Following Extension of Survival, PAA Prepares Phase 3 Trial, page-59

Bucky,

the "great science" was always a reference to the fact that PAA's work is underpinned by scientific work on monepantel use against cancer at the University of NSW and ONJCRI. it's that which gives me confidence in this program. Back in late 2020, when most were getting excited about a rapid rampup against covid, I was sceptical and called it a "moonshot" and from time to time I reminded people of Professor Peligrini's warning that "it is a long pipeline"

PAA has faced a number of hurdles in the last few years, beginning with Elanco's decision in 2020 to pull out its dog option and take back its monepantel supply, forcing PAA to come up with its own gmp monepantel, the interruption of the second dog trialing program by covid lockdowns, the need to further refine and develop the pills to account for the discovery of the bi-phasal properties of monepantel, the diversion into covid research (though note, this may still have a longer term payoff in viral usage) and finally the ethics related recruitment delay of about half a year for the current human MND trial. It's been a pretty hectic and confusing three years but now, the pharmacokinetics from this MND trial have shown us that we've got the pill we need for further human trials, including cancer where I'm quite optimistic but for now the focus should be on the three upcoming MND lab results announcements for the biomarkers, starting, hopefully, this week.